Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeMaria Antonietta Aloe Spiriti, Maria Concetta Petti, Roberto Latagliata et al.|Annals of Hematology|2004Cited by 110
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic SyndromesMaria Teresa Voso, Giuseppe Leone, Valeria Santini et al.|Clinical Cancer Research|2009Cited by 101
Zoledronic acid-associated thrombotic thrombocytopenic purpuraG. Ferretti, F. Cognetti, Maria Concetta Petti et al.|Annals of Oncology|2004Cited by 11
Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)Michèle Cavo, Michele Baccarani, Lucia Pantani et al.|Blood|2011Cited by 7
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDMAnnamaria Brioli, Michèle Cavo, Francesco Lanza et al.|Blood|2014Cited by 3